New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
09:16 EDTKO, PESI, HALO, MS, INFY, BHP, POT, ZBRA, MSI, JNJ, AANOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Coca-Cola (KO), up 2.2%... Johnson & Johnson (JNJ), up 2.1%. ALSO HIGHER: Zebra Technologies (ZBRA), up 5.5% after agreeing to acquire Motorola Solution's (MSI) enterprise unit for $3.45B. Motorola Solutions shares are up 3.5% following the news... Halozyme (HALO), up 8.5% after initiated with Buy rating at Citigroup... Potash (POT), up 2.3% after Globe & Mail says the company is speculated to be targeted again by BHP Billiton (BHP)... Morgan Stanley (MS), up 2% after upgraded at BofA Merrill Lynch. DOWN AFTER EARNINGS: Infosys (INFY), down 2.5%... Perma-fix (PESI), down 8.9%. ALSO LOWER: Aaron's (AAN), down 5% after cuttings Q1 EPS and revenue guidance, acquiring Progressive Finance Holdings for $700M, and rejecting Vintage Capital's takeover offer.
News For KO;JNJ;MSI;ZBRA;POT;BHP;INFY;MS;HALO;PESI;AAN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
October 13, 2014
15:24 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
15:23 EDTKOCoca-Cola Amatil could sell water brand to Coca-Cola, AFR says
Subscribe for More Information
14:24 EDTJNJJohnson & Johnson October volatility increases into Q3 and outlook
Subscribe for More Information
14:15 EDTJNJEarnings Preview: Johnson & Johnson looks to new drugs to boost Q3 sales
Subscribe for More Information
14:08 EDTJNJJohnson & Johnson technical notes before earnings
Subscribe for More Information
14:00 EDTAANCalifornia AG announces $28.4M settlement with Aaron's
Subscribe for More Information
12:01 EDTINFYOptions with decreasing implied volatility
Options with decreasing implied volatility: EXAS INFY YUM FDO HSY
10:26 EDTINFYHigh option volume stocks
Subscribe for More Information
10:08 EDTINFYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:40 EDTJNJAlios BioPharma reports positive results for AL-8176 in Phase 2 study
Alios BioPharma presented results from a randomized, double-blind, placebo-controlled Phase 2 challenge study of its oral anti-RSV nucleoside analog AL-8176 this past weekend at the IDWeek 2014 Conference in Philadelphia, PA. The study was conducted in healthy adult volunteers who were infected intranasally with respiratory syncytial virus, or RSV. AL-8176 achieved its primary and secondary endpoints of reduction in viral load and improvement in symptom scores as compared to placebo. AL-8176 was well tolerated with no discontinuations of study drug and no clinically significant laboratory abnormalities. In successfully infected subjects, a rapid and marked reduction in RSV viral load was observed following treatment in all three AL-8176 treated dose groups as compared to placebo. In contrast, successfully infected placebo subjects exhibited a logarithmic increase in RSV RNA with a peak viral load at Day 3.5 following start of dosing with placebo. The mean time to non-detectability of RSV RNA was 1.3-2.3 days for the AL-8176 treatment groups compared to 7.2 days in the placebo group. At discharge, all subjects treated with AL-8176 were RSV RNA undetectable and remained RSV RNA undetectable upon follow-up on Days 16 and 28. The viral load reduction in infected subjects across all AL-8176 dosing regimens was associated with concomitant improvements in RSV symptom scores and reductions in mucus weight. On September 30, Johnson & Johnson announced a definitive agreement to acquire Alios.
08:05 EDTJNJBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:51 EDTINFYInfosys upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
07:25 EDTJNJEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
07:15 EDTJNJNational Association of Corporate Directors to hold a conference
Subscribe for More Information
07:13 EDTJNJBioFlorida to hold a conference
Subscribe for More Information
06:44 EDTMSRegulators seeking banks' auto loan data, Reuters reports
Subscribe for More Information
06:37 EDTMSBlackRock, Morgan Stanley to buy shares in Link Net, WSJ reports
Subscribe for More Information
06:25 EDTMSMorgan Stanley may not close Rosneft deal, WSJ reports
Subscribe for More Information
06:11 EDTINFYInfosys upgraded to Buy from Hold at Deutsche Bank
October 12, 2014
13:03 EDTMSBanks agree on derivatives procedures for future crisis scenario, WSJ says
Meeting at the Federal Reserve in Washington, top banking executives from 18 large U.S., European and Japanese banks agreed in principle to wait up to 48 hours before seeking to terminate derivatives contracts and collect associated payments from a troubled financial institution, says the Wall Street Journal. Publicly traded companies in the space include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use